ARDX
HEALTHCAREArdelyx Inc
$7.10-0.03 (-0.42%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ARDX Today?
No stock-specific AI insight has been generated for ARDX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$3.21$8.40
$7.10
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-0.24
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume4.7M
Avg Volume (10D)—
Shares Outstanding247.0M
ARDX News
21 articles- Assessing Ardelyx (ARDX) Valuation After Q1 2026 Results And Reaffirmed Revenue GuidanceYahoo Finance·May 7, 2026
- Ardelyx Presents Analysis Supporting Long-Term Safety of XPHOZAH at NKF’s Spring Clinical MeetingsYahoo Finance·May 7, 2026
- Analyst Estimates: Here's What Brokers Think Of Ardelyx, Inc. (NASDAQ:ARDX) After Its First-Quarter ReportYahoo Finance·May 2, 2026
- Ardelyx Inc (ARDX) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic InvestmentsYahoo Finance·May 1, 2026
- Ardelyx, Inc. Q1 2026 Earnings Call SummaryMoby·May 1, 2026
- Ardelyx (ARDX) Q1 2026 Earnings TranscriptMotley Fool·Apr 30, 2026
- Ardelyx (ARDX) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·Apr 30, 2026
- Ardelyx Q1 Earnings Call HighlightsMarketbeat·Apr 30, 2026
- Compared to Estimates, Ardelyx (ARDX) Q1 Earnings: A Look at Key MetricsYahoo Finance·Apr 30, 2026
- Ardelyx Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·Apr 30, 2026
- Ardelyx Announces Abstract Accepted for Poster Presentation at the NKF’s Spring Clinical MeetingsYahoo Finance·Apr 27, 2026
- Is Ardelyx (ARDX) Offering Value After Recent Share Price Swings And DCF Estimate GapYahoo Finance·Apr 25, 2026
- Will Ardelyx (ARDX) Report Negative Earnings Next Week? What You Should KnowYahoo Finance·Apr 23, 2026
- Ardelyx Announces Abstract Exploring IBS-C Treatment Patterns Accepted for Poster Presentation at Digestive Disease Week 2026Yahoo Finance·Apr 23, 2026
- Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal OfficerYahoo Finance·Apr 20, 2026
- Ardelyx to Report First Quarter 2026 Financial Results on April 30, 2026Yahoo Finance·Apr 16, 2026
- Global Movement Takes Center Stage as "Champions Raise Awareness" for World IBS Day 2026Yahoo Finance·Apr 14, 2026
- Is Ardelyx (ARDX) Offering Long-Term Value After Recent Share Price Swings?Yahoo Finance·Apr 4, 2026
- Ardelyx CMO Appointment Tests Growth Plans For Tenapanor Based TherapiesYahoo Finance·Apr 4, 2026
- Ardelyx President and CEO Sells 41,000 Shares for $243,000The Motley Fool·Apr 3, 2026
- Rajani Dinavahi, MD, Appointed Chief Medical Officer of ArdelyxGlobeNewswire Inc.·Apr 1, 2026
All 21 articles loaded
Price Data
Open$7.16
Previous Close$7.13
Day High$7.39
Day Low$6.99
52 Week High$8.40
52 Week Low$3.21
52-Week Range
$3.21$8.40
$7.10
Fundamentals
Market Cap$1.8B
P/E Ratio—
EPS$-0.24
Dividend Yield—
Dividend / Share—
ROE-0.4%
Profit Margin-0.1%
Debt / Equity—
Trading
Volume4.7M
Avg Volume (10D)—
Shares Outstanding247.0M
About Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is headquartered in Fremont, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—